MONTHLY INTELLIGENCE | UPCOMING EVENTS | MEDIA DIRECTORY | CONFERENCES

MONTHLY HEALTHCARE NEWSLETTER - FEBRUARY 2020A GLOBAL LEADER IN STRATEGIC HEALTHCARE COMMUNICATIONSLondon | New York | Boston | San Francisco

VISIT WWW.CONSILIUM-COMMS.COM FOR MORE INTEL

MONTHLY INTELLIGENCE

Consilium speaks to Mary Kerr, CEO of Kandy Therapeutics, on the need for novel approaches to treat the symptoms of menopause as well as the wider challenges faced by companies operating in the women’s health space.

These are exciting times for Kandy Therapeutics? What are you most looking forward to? Yes indeed, this is an exciting time for the company as we now have further confirmation that NT-814, a novel non-hormonal drug candidate, has the potential to “switch off” multiple debilitating symptoms of the menopause. If this profile is confirmed in Phase 3 studies, NT-814 represents a true breakthrough in the field of women’s health. We are looking forward to discussing the Phase 2b data with the experts in the field and regulators in the US and Europe to agree the Phase 3 programme.

What has been the biggest challenge around working in women’s health? By far the biggest challenge is overcoming the widespread lack of understanding of just how debilitating the menopause is for millions of women on a daily basis. Menopausal symptoms spoil the lives of a large percentage of women for as long as 10 years at the peak of their professional productivity and at a time when quality of life should be improving rather than deteriorating. It was reported only last week that in the UK alone hundreds of thousands of women are wrongly prescribed antidepressants by GPs who mistake hormone imbalance for a mental health problem. It is reported that both healthcare professionals and patients fear hormone therapy and a non-hormonal alternative is urgently needed. Based on the evidence to date, NT-814 should offer this much needed alternative.

KANDY CAN DO:CHALLENGING STANDARDS OF CARE IN WOMEN'S HEALTH

What or who is your biggest inspiration as a CEO? Without doubt it’s my team, who are united in a common commitment to delivering quality in everything they do and willingness to collaborate and support each other. Equally I have had the great privilege to be part of the Galapagos Board for the last few years and observe the brilliant CEO Onno van de Stolpe in action. Onno is a force of nature and has built Galapagos, now the most valuable European biotech through his personal vision, single minded focus and persistence over many years.

What piece of advice would you give to someone starting their career today? Follow your passion, then work will be rewarding and less stressful. Try to be your authentic self, u nderstand who you are and what you have to offer – this is energising and sustainable for the long term. Do a Masters or PhD, education opens minds and doors. You are CEO of two Companies – NeRRe and KaNDY. What do you do to relax? My preferred way to relax is walking with my husband Clive and my eldest son’s French bulldog. Our favourite walks are by the River Lee in Hertfordshire, on Cleeve Hill in the Cotswolds or on Portstewart’s glorious beach where I grew up.

What was the last (good) book you read? I really enjoyed ‘Rebel Ideas: The Power of Diverse Thinking’ by Matthew Syed. He proposes that individual intelligence is not enough and that complex problems are best tackled by cognitively diverse teams who bring very different thoughts and perspectives, don’t always agree thus avoiding group think. I do believe that diversity is strength and coming from Northern Ireland have observed first-hand the importance of seeking out and respecting different opinions.

ANALYST AND SPECIALIST SALES MOVES – Martin Plenheimer joined Bryan Garnier's London Investment Banking Team

If you would like to receive our Monday Healthcare Bulletin, which summarises all healthcare business news from the weekend, please contact: admincsc@consilium-comms.com

THIS MONTH’S MOVERS AND SHAKERS

CONNAUGHT ROOMS WC2B19 NOVEMBER

If you would like to receive our Monday Healthcare Bulletin, which summarises all healthcare business news from the weekend, please contact:

admincsc@consilium-comms.com

CONSILIUM IS PROUD TO BE A MEMBER OF:

– Verona Pharma appointed Dr David Zaccardelli as CEO and Mark Hahn as CFO

– Polarean Imaging appointed Jonathan Allis as Chairman

– UDG Healthcare appointed Liz Shanahan to the Board of Directors

– Freeline appointed Theresa Heggie as Chief Executive

– Santhera Pharmaceuticals appointed Andrew Smith as CFO

– Ivenix appointed Jorgen Hansen as CEO

– Wexford appointed Daniel Kohler as CEO

– Panthera Biopartners appointed Stuart Young as CEO

– Bacthera AG appointed Lukas Schüpbach as CEO

– Mirum Pharmaceuticals appointed Ian Clements as CFO

– Disarm Therapeutics appointed

Scott Holmes as CFO – Campbell appointed Daniel Davis as COO

– Jiangsu Hengrui Medicine appointed Zhou Yunshu as Chairman

– Vyaire Medical appointed Gaurav Agarwal as CEO

– Krystal Biotech appointed Jennifer Chien as CCO

– Decibel Therapeutics appointed Laurence Reid as CEO

– Moderna appointed Melanie Ivarsson as CDO

– Passage Bio appointed Stephen Squinto as CEO

– Gilead Sciences appointed Sandra Horning to the Board of Directors

– Century Therapeutics appointed Joe Jimenez to the Board of Directors

– Poxel SA appointed David Moller as CSO

Consilium will be hosting a charity bake sale on 14th February 2020. All proceeds will be donated to the

British Heart Foundation.

SUPPORT CONSILIUM STAFF'S CHARITY INITIATIVES

HIGHLIGHTED FUNDRAISING ACTIVITY FROM JANUARY TO FEBRUARY 2020

COMPANY NAME AMOUNT RAISED

TYPE OF FUNDRAISE COUNTRY DATE

PUBLIC COMPANY FINANCINGS

Mirati Therapeutics Inc. $345 million Follow-on US 15-Jan-20

Adaptimmune Therapeutics plc $84 million Follow-on US 22-Jan-20

Blueprint Medicines Corp. $350 million Follow-on US 24-Jan-20

Zymeworks Inc. $279 million Follow-on Canada 24-Jan-20

Zai Lab Ltd. $261.3 million Follow-on US 24-Jan-20

Applied Therapeutics Inc. $124.7 million Follow-on US 24-Jan-20

Hutchison China MediTech Ltd. $110 million Follow-on US 24-Jan-20

Trillium Therapeutics Inc. $101.7 million Follow-on Canada 24-Jan-20

ImmunoGen Inc. $90.6 million Follow-on US 24-Jan-20

Adaptimmune Therapeutics plc $84 million Follow-on US 24-Jan-20

Autolus Therapeutics plc $80 million Follow-on US 24-Jan-20

Xenon Pharmaceuticals Inc. $60 million Follow-on US 24-Jan-20

Black Diamond Therapeutics Inc. $201.1 million IPO US 29-Jan-20

Biohaven Pharmaceutical Holding Co. Ltd. $250 million Follow-on US 29-Jan-20

Denali Therapeutics Inc. $180 million Follow-on US 29-Jan-20

Concert Pharmaceuticals Inc. $65 million Follow-on US 29-Jan-20

Annovis Bio Inc. $12 million IPO US 29-Jan-20

Sequana Medical €19 million Private placement Belgium 29-Jan-20

Alector Inc. $208.8 million Follow-on US 30-Jan-20

DBV Technologies S.A. $153.7 million Public offering France 30-Jan-20

BerGenBio $23.7 million Private placement Norway 30-Jan-20

Arcutis Biotherapeutics Inc. $159.4 million IPO US 31-Jan-20

Catalent Inc. $500 million Follow-on US 4-Feb-20

PRIVATE COMPANY FINANCINGS

Tyra Biosciences $50 million Series A US 14-Jan-20

Jasper Therapeutics Inc. $14.1 million Series A US 10-Dec-19

seqWell $9 million Series B US 15-Jan-20

Emendo Biotherapeutics Inc. $61 million Series B US 15-Jan-20

HepaRegeniX $12.2 million Series B Germany 18-Jan-20

PDC*line Pharma S.A.S. €13.9 million Series B France 22-Jan-20

iOnctura $16.6 million Series A Switzerland 24-Jan-20

Lyra Therapeutics Inc. $30 million Series C US 29-Jan-20

CellFE Inc. $3.6 million Initial seed US 29-Jan-20

Vizgen $14 million Series A US 30-Jan-20

BenchSci $22 million Series B Canada 4-Feb-20

Lightship $20 million Series B US 4-Feb-20

Inato $14 million Series A France 4-Feb-20

Outset Medical $125 million Series E US 4-Feb-20

Source: BioCentury

INVESTOR CONFERENCE EVENT CALENDAR

2020

FEBRUARYSachs13th Annual European Life Sciences CEO Forum, Zurich (19-20 February) Leerink Partners Global Healthcare Conference 2020, New York (25-27 February)

MARCHRaymond James Annual Institutional Investors Conference, Orlando (1-4 March) Cowen & Co. Annual Health Care Conference, Boston (2-4 March) Credit Suisse Healthcare One-on-One Conference, London (3-4 March) Morgan Stanley European MedTech & Services Conference, London (6 March) New York BIO Annual Conference, New York (10-11 March) BIO Asia International Conference, Tokyo (10-11 March) Barclays Capital Healthcare Conference, Miami (10-12 March) Roth Capital Partners Annual Conference, California (15-17 March) Oppenheimer & Co. Annual Healthcare Conference, New York (17-18 March) BIO-Europe Spring, Vienna (23-25 March) KBC Securities Healthcare Conference, Brussels (TBD)

APRILH.C. Wainwright Global Life Sciences Conference, London (6-7 April) BioCentury Future Leaders in the Biotech Industry, New York (10 April) ARM Cell & Gene Meeting on the Mediterranean, Barcelona (15-17 April) BioTrinity 2020, London (28-29 April) Kempen & Co. Life Sciences Conference, Amsterdam (TBD)

MAYBank of America Merrill Lynch 2020 Healthcare Conference, Las Vegas (1 May) Deutsche Bank Annual Healthcare Conference, Boston (1 May) ChinaBio Partnering Forum, Suzhou (6-7 May) Citi Swiss Healthcare Day, Zurich (7 May) BioEquity Europe, Barcelona (11-12 May) UBS Global Healthcare Conference, New York (18-20 May) RBC Capital Markets 2020 Healthcare Conference, New York (26-27 May)

JUNEJefferies Healthcare Conference, London (2-4 June) Goldman Sachs 40th Annual Global Healthcare Conference, Palos Verdes (9 June) Citi 8th Annual European Healthcare Conference, London (16-17 June) Piper Jaffray Heartland Summit, Minneapolis (17-18 June) JMP Securities Life Sciences Conference, New York (17-18 June) Biotech CEO Summit Europe, Enniskerry, Ireland (17-19 June) Next Generation CAR & T Cell Therapies, San Francisco (22-24 June) JP Morgan European Healthcare Conference, London (25 June) Bryan Garnier & Co. Annual Oncology Day, Paris (TBD)

JULYLSE Future of Healthcare Investment Forum, London (1 July) Biotech CEO Summit Napa, Napa (13-15 July)

AUGUSTCanaccord Genuity Annual Growth Conference, Boston (12-13 August)

SEPTEMBERCiti 15th Annual BioPharma Conference, Boston (9-10 September)RW Baird Healthcare Conference, New York (9-10 September)Wells Fargo Securities Healthcare Conference, Boston (9-10 September)Goldman Sachs Annual Biotech Symposium, London (11 September)Morgan Stanley Global Healthcare Conference, New York (14-16 September) CAR-TCR Summit Boston 2020, Boston, (14-17 September) Cell & Gene Therapy Manufacturing and Commercialization, Boston (21-24 September)Boston Biotech Week, Boston (21-24 September)Boston BioTech BD Conference, Boston (22 September) Annual HealthTech Investment Forum, Basel, (22 September)Sachs 20th Annual Biotech in Europe Forum, Basel (23-24 September) BAML Global Healthcare Conference, London (TBD) Cantor Global Healthcare Conference, New York (TBD)Rodman & Renshaw Annual Global Investment Conference, New York (TBD)BioCentury Annual Newsmakers in the Biotech Industry, New York (TBD)Ladenburg Thalman Healthcare Conference, New York (TBD)

You can view the full 2020 investor conference event calendar here

CONSILIUM STRATEGIC COMMUNICATIONSINTERNATIONAL HEALTHCARE COMMUNICATIONS

Leading international strategic PR and IR advisor

focused on healthcare

Trusted long-term relationships with clients,

Boards and advisors

Networked across all critical stakeholders

Europe’s largest specialist team with deep sector

knowledge

Experts across all sub-sectors

of healthcare

41 LOTHBURY | LONDON | EC2R 7HG NEW YORK | BOSTON | SAN FRANCISCO

+44 (0)20 3709 5700 info@consilium-comms.com www.consilium-comms.com

@ConsiliumHC

19 November Connaught Rooms WC2B